Liquidia Technologies Current Ratio 2018-2020 | LQDA

Liquidia Technologies current ratio from 2018 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Liquidia Technologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-09-30 $0.08B $0.01B 5.67
2020-06-30 $0.02B $0.01B 1.83
2020-03-31 $0.04B $0.02B 2.55
2019-12-31 $0.06B $0.02B 3.34
2019-09-30 $0.04B $0.01B 2.87
2019-06-30 $0.05B $0.01B 4.32
2019-03-31 $0.06B $0.01B 5.57
2018-12-31 $0.04B $0.01B 4.85
2018-09-30 $0.05B $0.01B 6.27
2018-06-30 $0.01B $0.02B 0.66
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.187B $0.001B
Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76